John B. Buse, MD, PhD - An Update on SGLT2 Inhibition for the Prevention and Treatment of Kidney Disease in Patients With Type 2 Diabetes - a podcast by PVI, PeerView Institute for Medical Education
from 2022-05-04T02:14:17.079004
Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education